What are PD-1 and PD-L1? PD-L1 is a protein on the surface of some cancer cells that interacts with the PD-1 protein on T cells of the immune system to thwart an immune attack on the cancer. It’s one of the tools that cancer cells use to escape an attack by the immune system and … Read more
Immunotherapy can be dramatically successful for people with limited options — so scientists are working on expanding the benefits to other patients.
It’s a compelling idea that has attracted scientists for decades: rather than poison tumors with chemicals and radiation, use a biological agent – a vaccine – to rally the body’s formidable immune defenders to kill cancer cells and shrink tumors. Yet, even as other forms of immunotherapy are showing promise against some cancers, efforts to … Read more
Cancers of the colon and rectum haven’t yet been as effectively treated with immunotherapy as have melanoma and lung cancer, but researchers are increasingly identifying patients who do appear to benefit from the immunity-boosting drugs – and devising strategies they hope will expand the reach of immunotherapy in colorectal cancers. Read More: Can Coffee Affect … Read more
In the high-stakes contest of hide-and-seek between cancer cells and the human immune system, the advantage doesn’t always lie with the body’s defenders. A new approach to treatment, known as CAR T-cell therapy, may shift that balance of power. Cancer cells conceal themselves from the immune system not by barricading themselves in an impenetrable shell, … Read more
Both chemotherapy and antibody agents are used in the treatment of cancer. In its broadest definition, cancer chemotherapy refers to any drug that destroys cancer cells or slows their growth and reproduction. As the “chemo” in their name suggests, however, true chemotherapy agents consist of chemicals that kill fast-growing cancer cells while generally sparing slower-growing … Read more
CAR T-cell therapy is a kind of cellular therapy, which uses a patient’s own immune system T cells to rally an attack on cancer. CAR T cells are made by removing T cells from the blood, modifying them in a lab to intensify the immune system’s natural response to cancer, and re-injecting them into the patient. CAR … Read more
Treatments that improve the immune system’s ability to recognize and kill cancer cells are known as immunotherapy. For certain patients with advanced bladder cancer, immunotherapy is proving effective, and several immunotherapy drugs are approved for use in such patients. Currently approved treatments A checkpoint inhibitor is a drug — often made of antibodies — that … Read more
It’s 19 months after being diagnosed with the aggressive brain tumor, glioblastoma, and Andrew Wall is itching to go back to work as a police officer. “Sitting around is not my thing,” says Wall, 53, who hasn’t yet been cleared to return to work as a police officer in Monroe, Connecticut – a job he has … Read more
In honor of Brain Tumor Awareness Month, David Reardon, MD, and Patrick Wen, MD, of Dana-Farber’s Center for Neuro-Oncology, went live on Facebook to answer questions about brain cancer. The doctors discussed advice for brain tumor patients, answered audience questions, and described the difference between the two major categories of brain cancers—primary cancer, developed in … Read more
A PD-L1 test helps doctors determine whether a patient is likely to benefit from cancer drugs known as immune checkpoint inhibitors. It involves sending a piece of tumor tissue to a lab for analysis. What is PD-L1? PD-L1 is a protein that allows some cells to escape an attack by the immune system. Extending from the … Read more
If the human immune system was a powerful racing car, you could say that scientists in the past few years have gained unprecedented control over how to make it accelerate, and what causes it to slow or stop. This knowledge has spawned new immunotherapy drugs that are delivering dramatic benefits to some patients with advanced … Read more
For patients with advanced head and neck cancers, immune-based therapies have started to show results against these hard-to-treat tumors. Two immunotherapy drugs were approved in 2016 for use when standard treatments failed, and many other agents are being tested in clinical trials. Immunotherapies work by enhancing the body’s natural defenses against malignancies, and have made … Read more
The Food and Drug Administration (FDA) approved a new kind of immunotherapy drug for adults and children with classical Hodgkin lymphoma who have relapsed after three or more prior lines of therapy. The approved drug, pembrolizumab (Keytruda), is part of a class of immunotherapy drugs called checkpoint inhibitors that block the PD-1 protein, which is … Read more
Kidney cancer is one of several cancers that has responded well to immunotherapy drugs, which can free the immune system from restraints that cancer cells can impose on it. The drug nivolumab (Opdivo), for example, which was recently approved, can extend survival in patients with metastatic kidney cancer after other drugs have failed. But can … Read more
This post originally appeared on Cancer Research Catalyst, the official blog of the American Association for Cancer Research. It was originally published Jan. 10, 2017. By Srivani Ravoori, PhD As we step into 2017, a big question looming in the minds of all stakeholders in the cancer research arena is: What is the future of … Read more
Patients with pancreatic cancer often ask Dana-Farber’s Brian Wolpin, MD, MPH, about immunotherapy, the rising star of cancer treatment that’s making impressive gains against many types of malignancies. Immunotherapy drugs, which mobilize the patient’s immune defenses to recognize and attack tumor cells, have worked against lethal cancers such as melanoma and some lung cancers – … Read more
This post originally appeared on Cancer Research Catalyst, the official blog of the American Association of Cancer Research. It was originally published Nov. 15, 2016. By Karen Honey, PhD On Thursday, the U.S. Food and Drug Administration (FDA) announced that it had approved expanding the use of the immunotherapeutic nivolumab (Opdivo) to include the treatment … Read more
Combination therapy, the use of more than one type of therapy in treating a patient, is a hallmark of cancer treatment. The complexity of the disease – its tendency to spread beyond its original site and become resistant to certain drugs, and its genetic diversity – underscores the need for a variety of approaches to … Read more
The immunotherapy drug pembrolizumab (Keytruda) is the first therapy of any kind to improve survival in patients whose metastatic bladder cancer worsened after treatment with platinum-based chemotherapy. Keytruda proved so much better than chemotherapy in this “second-line” use that an international clinical trial was halted when the advantage became apparent. “This is very good news; … Read more